Compare VSEC & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSEC | RGEN |
|---|---|---|
| Founded | 1959 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.6B |
| IPO Year | 1995 | 1995 |
| Metric | VSEC | RGEN |
|---|---|---|
| Price | $213.28 | $157.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $226.29 | $167.67 |
| AVG Volume (30 Days) | 377.7K | ★ 1.2M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.25% | N/A |
| EPS Growth | N/A | ★ 286.96 |
| EPS | ★ 1.04 | 0.24 |
| Revenue | ★ $760,113,000.00 | $141,236,000.00 |
| Revenue This Year | $32.16 | $14.30 |
| Revenue Next Year | $21.36 | $14.52 |
| P/E Ratio | ★ $207.45 | $660.79 |
| Revenue Growth | 9.88 | ★ 35.10 |
| 52 Week Low | $152.65 | $100.99 |
| 52 Week High | $240.56 | $175.77 |
| Indicator | VSEC | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 57.40 | 64.02 |
| Support Level | $163.12 | $128.08 |
| Resistance Level | $229.74 | $170.17 |
| Average True Range (ATR) | 9.37 | 8.07 |
| MACD | 1.37 | 0.83 |
| Stochastic Oscillator | 87.69 | 96.98 |
VSE Corp is a diversified aftermarket products and services company serving commercial and government markets. The Company's operations include aircraft and airframe parts supply and distribution, and MRO services of aircraft components and engine accessories. The Company operates as a single reportable segment: Aviation, which is a provider of aftermarket parts distribution and MRO services for components and engine accessories supporting commercial, business, and general aviation operators.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.